Experience built
for
rare disease

Chris Peetz is a co-founder of Mirum and serves as chief executive officer. Chris’ leadership of Mirum has been shaped by the experiences of rare disease patients and families, with a focus on bringing forward high-impact medicines for overlooked populations. Since the company’s founding in 2018, he has guided its growth into a global organization with a diversified portfolio and a strong commitment to improving diagnosis, access, and patient outcomes.

Chris co-founded Mirum while serving as entrepreneur-in-residence at Frazier Healthcare Partners. Prior to Mirum, Chris served as chief executive officer of Flashlight Therapeutics, Inc. He also previously served as chief financial officer and head of corporate development at Tobira, which was acquired by Allergan plc. Prior to joining Tobira, Chris served as vice president, finance and corporate development of Jennerex Biotherapeutics. Prior to Jennerex, Chris held various positions at Onyx Pharmaceuticals, Inc. (now Amgen Inc.), including corporate strategy, marketing, product lifecycle management, and financial planning. Prior to Onyx, Chris provided merger and acquisition advisory services at LaSalle Corporate Finance, a part of ABN AMRO, and held positions at Abgenix Inc. and Solazyme Inc. He also served as a member of the board of directors of Alpine Immune Sciences, Inc., a public immunotherapy company, until its sale to Vertex.

Chris received an M.B.A. from Stanford Graduate School of Business and a B.S.B.A. in finance, international business, and French from Washington University in St. Louis.

Eric Bjerkholt joined Mirum as chief financial officer in September 2023. Eric joined Mirum from Chinook Therapeutics, Inc., where he served as chief financial officer overseeing financial reporting, planning and budgeting, internal controls, investor relations, facilities, and information technology functions. Prior to Chinook, he served as CFO of Aimmune Therapeutics, Inc., Sunesis Pharmaceuticals, Inc., IntraBiotics Pharmaceuticals, Inc., LifeSpring Nutrition, Inc., and Age Wave, LLC. Prior to joining industry, Eric spent nearly a decade in healthcare investment banking at J.P. Morgan & Company, Inc. He is currently a member of the board of directors of Cerus Corporation, Metagenomi Therapeutics, Inc., and Surrozen, Inc.

Eric holds an M.B.A. from Harvard Business School and a Cand. Oecon. degree from the University of Oslo in Norway.

Erin Campany joined Mirum in 2019 and currently serves as chief people officer, where she is responsible for the company’s global human resources function, including talent acquisition, employee engagement, leadership development, and company culture. Erin brings more than 20 years of human resources leadership experience focused on shaping people strategies to drive business growth and optimize the employee experience to meet Mirum’s goals and objectives.

Prior to Mirum, Erin served as head of human resources at Immune Design (acquired by Merck). From 2013-2017, she oversaw Global Human Resources for Biotie Therapeutics (now Acorda Therapeutics) and also served an integral role during the company’s integration following its acquisition by Acorda. Erin held similar roles at VaxGen, Inc. and Exelixis and served as a human resources consultant to biotechnology companies throughout the Bay Area.

Erin has a bachelor’s degree in industrial psychology from San Jose State University.

Michael Ehrman joined Mirum in 2020 and currently serves as executive vice president and general manager, North America. Michael is an experienced biopharmaceutical leader with expertise in rare disease, leading Mirum through successful product launches and lifecycle management.

Most recently, Michael served as senior director and U.S. brand lead for Yescarta at Kite, a Gilead company, where he was responsible for commercial strategy, cross-functional brand leadership, and multiple indication launches. Prior to this, he held several senior leadership roles at Kite and Gilead, including global commercial lead for the B-cell franchise, where he led global brand strategy, lifecycle planning, and cross-regional commercialization efforts.

Michael previously held leadership positions at Amgen and Onyx Pharmaceuticals across U.S. marketing, global product strategy, and medical affairs. He began his career in clinical research roles at Amgen and Brigham and Women’s Hospital.

Michael holds an M.S. in research exercise physiology from Springfield College and a B.A. in biochemistry and molecular biology from Boston University.

Jean-Luc Girardet joined Mirum in 2022 and serves as chief technical officer, overseeing chemistry, manufacturing, and controls (CMC) and global supply chain (clinical and commercial). Jean-Luc brings more than 25 years of operational and technical experience in the biotech and pharmaceutical industry.

Prior to joining Mirum, Jean-Luc served as senior vice president of pharmaceutical sciences at Brii Biosciences from inception (2018) to 2022. From 2007 to 2018, he worked at Ardea Biosciences, a member of the AstraZeneca Group, serving in a variety of executive leadership roles, including vice president of pharmaceutical and translational sciences, leading the progression of Ardea’s internal discovery programs from concept to clinical development and eventually to regulatory approval. He also led the CMC teams through clinical phases, FDA approval, and launch readiness of Zurampic^® and Duzallo^®.  Earlier in his career, Jean-Luc was at Valeant Pharmaceuticals, Ribapharm, and ICN Pharmaceuticals.  

Jean-Luc completed a Postdoctoral Fellowship at the University of Michigan in Ann Arbor, Michigan, and he received a Ph.D. in chemistry and a B.S. in chemistry and biochemistry from the University of Montpellier II, France. He co-authored more than 45 publications and book chapters and has been issued 35 U.S. patents.

Hassan Javanbakht, Ph.D., received his Ph.D. from McGill University and completed his post-doctoral fellowship at Harvard Medical School. He then moved to Hoffmann-La Roche Palo Alto LLC where he worked on developing antivirals to treat HIV infection. He was part of the team that advanced Elipida^® (RO4970335), a potent and highly selective non-nucleoside reverse transcriptase inhibitor (NNRTI), into clinical development. He then transferred to Hoffmann-La Roche where he began his work on hepatitis B virus (HBV) and Influenza. His group there focused on developing novel direct-acting antivirals and immunomodulatory therapies to treat chronic HBV. He led the teams that developed a first-in-class small-molecule viral expression inhibitor (RG7834), a liver-targeted anti-HBV locked nucleic acid (RG6004), and an immunomodulator, all of which advanced to Phase 1 clinical evaluation.

His work also led to the discovery of PAPD5/7 as host factors for HBV expression. Subsequently, he moved to Gilead Sciences where he led a research team focused on curing HBV and developing a number of novel therapeutics scheduled to enter clinical studies. He was the head of infectious diseases at SQZ Biotechnologies leading a group of scientists developing cell-based vaccines for treatment of persistent viral infections. Most recently, he served as the chief scientific officer at Bluejay Therapeutics. So far, he has authored more than 45 peer-reviewed scientific publications in high-impact journals and holds more than 11 issued patents and applications.

Vinita Kumar currently serves as senior vice president of quality, where she oversees GxP quality operations within clinical, laboratory, document control, training, and IT systems. She is responsible for creating and implementing Mirum’s global inspection readiness strategies, including oversight of the quality management system implementation and maintenance. Vinita brings more than 30 years of experience in building effective quality teams, successfully transitioning from early to late-stage programs into commercialization.

Prior to Mirum, she served in similar quality leadership roles at Corcept Therapeutics, Versartis, and Relypsa. Earlier in her career, she worked at numerous Bay Area-based biotech companies, including Syntex/Roche in pre-formulation, analytical development, manufacturing, and quality control roles.

Vinita holds an M.S. in physical organic chemistry from Southern Illinois University and both an M.S. in organic chemistry and an undergraduate degree from Patna University.

Lara Longpre joined Mirum in 2018 as chief development officer and is responsible for program leadership, global regulatory affairs, biometrics, and medical writing. She brings more than 30 years of experience in the biopharmaceutical industry, helping develop innovative and complex therapies.

Prior to Mirum, she served as chief operating officer at MedGenesis Therapeutix and Jennerex Biotherapeutics, where she held responsibilities for program management, alliance management, clinical operations, technical operations, regulatory affairs, and quality assurance. She previously held several leadership roles in Contract Research Organizations including PRA International and CroMedica International, where she was responsible for clinical operations and project management, global regulatory affairs, and proposals and contracts.

Lara received an M.M.Sc. from Harvard Medical School, an M.B.A. from Queen’s University in Ontario, Canada, and her undergraduate degree in biology from Cornell University.

Joanne Quan, M.D., joined Mirum in 2024 as chief medical officer and is responsible for clinical development, clinical operations, and safety, while also leading Mirum’s nonclinical and clinical pharmacology teams. Joanne has nearly three decades of experience developing novel therapeutics across all phases of development, including those in rare diseases.

Prior to Mirum, she served as chief medical officer at Nuvig Therapeutics. From 2018 to 2021, she served in the same role at Modis Therapeutics, a company focused on rare genetic diseases (acquired by Zogenix, Inc., and subsequently, UCB). Before Modis, she held clinical development leadership positions at Eiger Biopharmaceuticals, InterMune, Arena Pharmaceuticals, Bayhill Therapeutics, ALZA Corporation (Johnson & Johnson), Genentech, and PathoGenesis.

Joanne received a B.A. in molecular biology from the University of California, Berkeley, and an M.D. from Stanford University School of Medicine. She completed a residency in internal medicine at Massachusetts General Hospital and a fellowship in pulmonary and critical care medicine at the University of Washington. 

Peter Radovich currently serves as president and chief operating officer at Mirum, where he is responsible for corporate development, U.S. and international commercial, medical affairs, and patient advocacy. Peter joined Mirum in April 2020 as chief operating officer with more than 20 years of experience in the biopharmaceutical industry.

Prior to Mirum, he served as executive vice president, operations at Global Blood Therapeutics (GBT) from 2014 to 2020, where he was responsible for program leadership and management, commercial strategy, technical operations, supply chain, and quality assurance. From 2006 to 2014, Peter worked at Onyx Pharmaceuticals, Inc. (now Amgen, Inc.), serving in various roles including vice president, program leadership, and several commercial positions. Prior to Onyx, Peter held product marketing roles at Chiron Corporation (now Novartis AG).

Peter received an M.B.A. from Washington University in St. Louis and his undergraduate degree in biology and chemistry from Texas Christian University.

Doug Sheehy joined Mirum as chief legal officer and secretary in May 2025. Doug joined Mirum from Sonoma Biotherapeutics, Inc., where he served as chief legal officer and secretary, with responsibility for legal, human resources, quality, and regulatory functions. Prior to Sonoma, he was general counsel and secretary at Aimmune Therapeutics, Inc. until its acquisition by Nestle Health Science. Before Aimmune, he served in similar roles in legal at Codexis, Inc. and CV Therapeutics, Inc. He began his career as a corporate and securities lawyer in Silicon Valley representing emerging growth companies and venture funds at Gunderson Dettmer.  

Doug received an A.B. in History from Dartmouth College and a J.D. from American University’s Washington College of Law, where he was Editor-in-Chief of the American University Law Review.

Nancy Shulman currently serves as Mirum’s executive vice president of clinical and has over 20 years of clinical development experience. Prior to Mirum, she worked at Roche, Genentech, AbbVie, Ambys Medicines, and most recently, Bluejay Therapeutics, where she served as chief medical officer. She brings broad clinical development experience ranging from first-in-human and translational studies through Phase 4, with extensive expertise in virology, hepatology, immunology, and oncology. She has been part of multiple INDs and was a key leader on the approvals of the HCV antivirals Viekira Pak^®, Viekirax^® and Mavyret^®.

Previously, Nancy was an NIH-funded clinical/translational HIV researcher at Stanford University and was on the faculty in the Division of Infectious Diseases. She holds a B.A. in biochemistry with a minor in Chinese from the University of Texas at Austin and an M.D. from the University of Kansas. She completed her residency in internal medicine and pediatrics at the University of Chicago and her infectious disease fellowship at Stanford.